Ellen Bower Joins Parallel ENT & Allergy as CEO

LISLE, Ill., Feb. 3, 2025 /PRNewswire/ -- Parallel ENT & Allergy, a leading physician-centric practice management organization for ENT and allergy practices, announces the appointment of Ellen Bower as Chief Executive Officer. With a distinguished career in healthcare leadership and a proven track record of driving organizational growth and operational excellence, Ms. Bower is poised to lead Parallel into its next phase of expansion and innovation.

Parallel ENT & Allergy partners with ear, nose, throat, allergy, and audiology practices to deliver comprehensive non-clinical management services, enabling providers to focus on delivering exceptional patient care. The organization currently supports more than 100 providers and 450 employees across 25 locations in five states, with plans for continued growth in the ENT and allergy care market.

Ms. Bower brings extensive experience in leading multi-site healthcare organizations. Most recently, she served as CEO of Ever/Body, a leading cosmetic dermatology platform with locations throughout the Northeast, where she successfully enhanced the business by focusing on operational efficiencies and organic growth. Prior to that, she held the role of COO at Women's Care, a national multi-site women's health organization, where she spearheaded strategic initiatives that drove significant growth and operational enhancements. Her career also includes leadership roles overseeing healthcare operations across diverse specialties, including expertise in health information systems, compliance, and privacy functions.

"We are delighted to welcome Ellen Bower as the new CEO of Parallel ENT & Allergy," said William Sheppard, M.D., partner at ENT and Allergy of Delaware and Chief Partnership Officer at Parallel ENT & Allergy. "Ellen's exceptional leadership experience and proven ability to scale healthcare organizations make her the ideal leader to drive Parallel's mission of supporting ENT and allergy practices nationwide. Her vision for growth and operational excellence aligns perfectly with our goal of becoming the premier platform in the ENT and allergy space."

"I am honored to join Parallel ENT & Allergy as CEO," said Ms. Bower. "This is an incredible opportunity to lead a dynamic team of experts and partner physicians dedicated to advancing ENT and allergy care. I am excited to build on the organization's strong foundation and drive continued growth, ensuring that we remain the trusted partner for practices seeking unparalleled management support."

Parallel ENT & Allergy is supported by Trinity Hunt Partners, a growth-oriented private equity firm with extensive healthcare expertise.

About Parallel ENT & Allergy

Parallel ENT & Allergy is a physician-centric practice management organization for ENT and allergy practices. Parallel provides strategic, operational, and administrative support, so physicians can spend less time worrying about the business of medicine and more time caring for their patients. To learn more about Parallel ENT & Allergy, or to inquire about becoming a supported practice, visit https://parallelenta.com.

About Trinity Hunt Partners

Trinity Hunt Partners is a growth-oriented private equity firm with over $2 billion of assets under management focused on building leading business, healthcare, and consumer services companies. Trinity Hunt's mission is to provide the talent and strategic, operational, and financial capabilities needed to build entrepreneurial services companies into market leaders. Trinity Hunt was ranked eighth amongst all firms in North America on HEC-Dow Jones' most recent Top Small-Cap Buyout Firms List (2023), which ranks firms based on their performance for investors across funds raised over a 10-year period[1]. For more information, visit www.trinityhunt.com.  

[1]Revealed: The top 20 global small-cap private equity firms; Trinity Hunt Partners was ranked 8th amongst all firms in North America on the most recent HEC-Dow Jones Top Small-Cap Buyout Firms List (2023), which ranked firms based on their performance across funds raised over a 10-year period between 2010 and 2019. In total, performance data was analyzed across 632 PE firms through data sourced from Prequin, a third-party database neither managed by nor affiliated with Trinity Hunt Partners, as well as data sourced directly to HEC/Dow Jones. Neither HEC nor Dow Jones is affiliated with Trinity Hunt Partners, nor do they invest in any investment vehicle sponsored by Trinity Hunt Partners.

Press Contact:
Suz Murphy
VP Digital Patient Experience & Marketing
Parallel ENT & Allergy
[email protected]
630.667.7587

SOURCE Parallel ENT & Allergy